BR112023022883A2 - Moduladores de pkc-teta - Google Patents
Moduladores de pkc-tetaInfo
- Publication number
- BR112023022883A2 BR112023022883A2 BR112023022883A BR112023022883A BR112023022883A2 BR 112023022883 A2 BR112023022883 A2 BR 112023022883A2 BR 112023022883 A BR112023022883 A BR 112023022883A BR 112023022883 A BR112023022883 A BR 112023022883A BR 112023022883 A2 BR112023022883 A2 BR 112023022883A2
- Authority
- BR
- Brazil
- Prior art keywords
- pkc
- theta
- modulators
- compounds
- syndromes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Amplifiers (AREA)
- Optical Communication System (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB202106486 | 2021-05-06 | ||
| PCT/GB2022/051167 WO2022234299A1 (en) | 2021-05-06 | 2022-05-06 | Pkc-theta modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022883A2 true BR112023022883A2 (pt) | 2024-01-23 |
Family
ID=82100804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022883A BR112023022883A2 (pt) | 2021-05-06 | 2022-05-06 | Moduladores de pkc-teta |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240239794A1 (https=) |
| EP (1) | EP4334316A1 (https=) |
| JP (1) | JP2024518447A (https=) |
| KR (1) | KR20240024063A (https=) |
| CN (1) | CN117295738A (https=) |
| AU (1) | AU2022269348A1 (https=) |
| BR (1) | BR112023022883A2 (https=) |
| CA (1) | CA3214088A1 (https=) |
| CL (1) | CL2023003247A1 (https=) |
| CO (1) | CO2023015005A2 (https=) |
| IL (1) | IL307669A (https=) |
| MX (1) | MX2023013012A (https=) |
| PE (1) | PE20250019A1 (https=) |
| WO (1) | WO2022234299A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022234298A1 (en) * | 2021-05-06 | 2022-11-10 | Exscientia Ai Limited | Pkc-theta modulators |
| CN118772140B (zh) * | 2023-04-07 | 2026-04-17 | 四川大学 | 一类化合物及其在治疗hDHODH介导的疾病中的用途 |
| WO2025255294A1 (en) * | 2024-06-06 | 2025-12-11 | Bristol-Myers Squibb Company | Pkc-theta inhibitors, compositions, and methods of use |
| WO2025255298A1 (en) * | 2024-06-06 | 2025-12-11 | Bristol-Myers Squibb Company | Pkc-theta inhibitors, compositions, and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200924762A (en) * | 2007-11-02 | 2009-06-16 | Vertex Pharma | Kinase inhibitors |
| GB0920382D0 (en) | 2009-11-20 | 2010-01-06 | Univ Dundee | Design of molecules |
| CN102471342A (zh) * | 2010-05-05 | 2012-05-23 | 沃泰克斯药物股份有限公司 | 用作PKC-θ抑制剂的4取代的吡唑并吡啶类 |
| US9556126B2 (en) | 2013-12-20 | 2017-01-31 | Signal Pharmaceuticals, Llc | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith |
| AU2020284742B2 (en) * | 2019-05-28 | 2026-03-05 | Mankind Pharma Ltd. | Novel compounds for inhibition of Janus Kinase 1 |
| WO2022234298A1 (en) * | 2021-05-06 | 2022-11-10 | Exscientia Ai Limited | Pkc-theta modulators |
-
2022
- 2022-05-06 PE PE2023002994A patent/PE20250019A1/es unknown
- 2022-05-06 AU AU2022269348A patent/AU2022269348A1/en active Pending
- 2022-05-06 IL IL307669A patent/IL307669A/en unknown
- 2022-05-06 JP JP2023568613A patent/JP2024518447A/ja active Pending
- 2022-05-06 CA CA3214088A patent/CA3214088A1/en active Pending
- 2022-05-06 BR BR112023022883A patent/BR112023022883A2/pt unknown
- 2022-05-06 US US18/557,865 patent/US20240239794A1/en active Pending
- 2022-05-06 WO PCT/GB2022/051167 patent/WO2022234299A1/en not_active Ceased
- 2022-05-06 CN CN202280033111.5A patent/CN117295738A/zh active Pending
- 2022-05-06 MX MX2023013012A patent/MX2023013012A/es unknown
- 2022-05-06 EP EP22731282.4A patent/EP4334316A1/en active Pending
- 2022-05-06 KR KR1020237041626A patent/KR20240024063A/ko active Pending
-
2023
- 2023-11-02 CL CL2023003247A patent/CL2023003247A1/es unknown
- 2023-11-03 CO CONC2023/0015005A patent/CO2023015005A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL307669A (en) | 2023-12-01 |
| KR20240024063A (ko) | 2024-02-23 |
| CA3214088A1 (en) | 2022-11-10 |
| WO2022234299A1 (en) | 2022-11-10 |
| AU2022269348A1 (en) | 2023-10-26 |
| CN117295738A (zh) | 2023-12-26 |
| MX2023013012A (es) | 2024-03-25 |
| CL2023003247A1 (es) | 2024-04-26 |
| US20240239794A1 (en) | 2024-07-18 |
| CO2023015005A2 (es) | 2024-02-05 |
| JP2024518447A (ja) | 2024-05-01 |
| EP4334316A1 (en) | 2024-03-13 |
| PE20250019A1 (es) | 2025-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023022883A2 (pt) | Moduladores de pkc-teta | |
| MX2023005928A (es) | Moduladores de malt-1. | |
| BR112023022706A2 (pt) | Moduladores de pkc-teta | |
| MX392673B (es) | Derivados de pirazol como inhibidores de malt1 | |
| BR112021021754A2 (pt) | Cicloalquilas substituídas como moduladoras da via de estresse integrada | |
| PH12020550524A1 (en) | Modulators of the integrated stress pathway | |
| BR112022004802A2 (pt) | Moduladores de il-17a e usos dos mesmos | |
| PH12021552759A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| BR112021012829A2 (pt) | Composições e métodos para modular o crescimento capilar | |
| MX2020013699A (es) | Derivados de pirazol como inhibidores de malt1. | |
| BR112021019799A2 (pt) | Derivados contendo anéis de piridina como inibidores de malt1 | |
| BR112012000968B8 (pt) | composto, composição e método para inibir uma fosfatidil inositol-3 cinase. | |
| JOP20250149A1 (ar) | مثبطات malt1 | |
| BR112017007014A2 (pt) | derivados de benzotiofenila substituídos como agonistas do gpr40 para o tratamento de diabetes tipo ii | |
| PH12020552172A1 (en) | Cyclic dinucleotides as sting agonists | |
| ES2193746T3 (es) | Acelerantes para sistemas reticulables. | |
| ZA202310843B (en) | Chromene derivatives as inhibitors of tcr-nck interaction | |
| BR112013003121A2 (pt) | moduladores de trpv3 | |
| BR112022003405A2 (pt) | Inibidores de di-hidro-oratato desidrogenase de ureia substituídas | |
| BR112021019448A2 (pt) | Métodos para o tratamento de beta-talassemia | |
| BR112021022960A2 (pt) | Derivados de heterociclo fundidos como moduladores da montagem do capsídeo | |
| BR112021023710A2 (pt) | Derivados de diazepinona como moduladores da montagem do capsídeo | |
| BR112021023456A2 (pt) | Difluoro azepanos como moduladores de montagem de capsídeo de hbv | |
| BR112021023651A2 (pt) | Azepinas como moduladores de montagem de capsídeo de hbv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: EXSCIENTIA AI LIMITED (GB) |
|
| B25A | Requested transfer of rights approved |
Owner name: CELGENE CORPORATION (US) |